标题
Glucagon and heart in type 2 diabetes: new perspectives
作者
关键词
T2D, Glucagon, Heart failure
出版物
Cardiovascular Diabetology
Volume 15, Issue 1, Pages -
出版商
Springer Nature
发表日期
2016-08-27
DOI
10.1186/s12933-016-0440-3
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
- (2016) Oliver Schnell et al. Cardiovascular Diabetology
- Drugs That May Cause or Exacerbate Heart Failure
- (2016) Robert L. Page et al. CIRCULATION
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction
- (2016) Kenneth B. Margulies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Hepatic glycogen can regulate hypoglycemic counterregulation via a liver-brain axis
- (2016) Jason J. Winnick et al. JOURNAL OF CLINICAL INVESTIGATION
- A Multicenter Observational Study of Incretin-based Drugs and Heart Failure
- (2016) Kristian B. Filion et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction
- (2016) John J. Lepore et al. JACC-Heart Failure
- Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus
- (2016) Darren K. McGuire et al. JAMA Cardiology
- Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications
- (2015) Sho-ichi Yamagishi et al. Cardiovascular Diabetology
- SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
- (2015) Silvio E Inzucchi et al. Diabetes & Vascular Disease Research
- Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes
- (2015) M. D. Sharma DIABETES OBESITY & METABOLISM
- Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
- (2015) Ele Ferrannini et al. EUROPEAN HEART JOURNAL
- The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial
- (2015) Caroline K. Kramer et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Lack of glucagon receptor signaling and its implications beyond glucose homeostasis
- (2015) M. J. Charron et al. JOURNAL OF ENDOCRINOLOGY
- Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
- (2015) Faiez Zannad et al. LANCET
- DPP-4 inhibitors and risk of heart failure EXAMINEd
- (2015) Eberhard Standl et al. LANCET
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
- (2015) Caroline Bonner et al. NATURE MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucagon – Early breakthroughs and recent discoveries
- (2015) Bo Ahrén PEPTIDES
- Understanding EMPA-REG OUTCOME
- (2015) Antonio Ceriello et al. Lancet Diabetes & Endocrinology
- Pancreatic α-Cell Dysfunction in Type 2 Diabetes: Old Kids on the Block
- (2015) Jun Sung Moon et al. Diabetes & Metabolism Journal
- Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
- (2014) Benjamin M. Scirica et al. CIRCULATION
- New Developments in Diabetes Management: Medications of the 21st Century
- (2014) Vivian A. Fonseca CLINICAL THERAPEUTICS
- Liraglutide and the Preservation of Pancreatic β-Cell Function in Early Type 2 Diabetes: The LIBRA Trial
- (2014) Ravi Retnakaran et al. DIABETES CARE
- Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus
- (2014) M. Hompesch et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
- (2014) Aurora Merovci et al. JOURNAL OF CLINICAL INVESTIGATION
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Saxagliptin, Alogliptin, and Cardiovascular Outcomes
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- The role of glucagon on type 2 diabetes at a glance
- (2014) Amélio F Godoy-Matos Diabetology & Metabolic Syndrome
- Sitagliptin Use in Patients With Diabetes and Heart Failure
- (2014) Daniala L. Weir et al. JACC-Heart Failure
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Minireview: Glucagon in Stress and Energy Homeostasis
- (2012) B. J. Jones et al. ENDOCRINOLOGY
- Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover
- (2012) Roger H. Unger et al. JOURNAL OF CLINICAL INVESTIGATION
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- Glucagon Effects on Ischemic Vasodilatation in the Isolated Rat Heart
- (2010) Mirko Rosic et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- The metabolic actions of glucagon revisited
- (2010) Kirk M. Habegger et al. Nature Reviews Endocrinology
- Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes
- (2008) Safina Ali et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search